2023
Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure
Souza A, Rosenthal M, Moura F, Divakaran S, Osborne M, Hainer J, Dorbala S, Blankstein R, Di Carli M, Taqueti V. Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure. JACC Cardiovascular Imaging 2023, 17: 179-191. PMID: 37768241, PMCID: PMC10922555, DOI: 10.1016/j.jcmg.2023.07.014.Peer-Reviewed Original ResearchConceptsCoronary microvascular dysfunctionVisceral adipose tissueAssociated with coronary microvascular dysfunctionCoronary flow reserveBody mass indexLow coronary flow reserveSubcutaneous adipose tissueCoronary artery diseaseAdverse eventsPositron emission tomographyObese patientsMicrovascular dysfunctionVisceral adipose tissue cross-sectional areaCardiovascular eventsHeart failurePreserved left ventricular ejection fractionAdverse outcomesSkeletal muscleArtery diseaseFlow-limiting coronary artery diseaseBody compositionAssociated with body compositionEvaluation of coronary artery diseaseStress positron emission tomographyEmission tomography
2022
Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model
Carvalho L, Nogueira A, Antunes J, Moura F, Luchiari B, Bonilha I, Nadruz W, Gaziano M, Gaziano T, Sposito A. Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model. Circulation 2022, 146: a14830-a14830. DOI: 10.1161/circ.146.suppl_1.14830.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGLP-1RAMiddle-income countriesType 2 diabetesCardiovascular eventsRisk of non-fatal cardiovascular eventsFollow-up >Pre-specified endpointsCohort of T2D patientsNon-fatal cardiovascular eventsGlucose-lowering therapySecondary prevention cohortAdverse cardiovascular eventsAnti-diabetic therapyRandomized clinical trialsCost-effectiveness ratioBrazilian public health systemDouble-blindGLP1-RAPublic health systemPrevention cohortProspective cohortT2D subjectsHeart failureT2D patientsEvolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Sposito A, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo H, Munhoz D, Oliveira D, Coelho-Filho O, Coelho O, Matos-Souza J, Moura F, de Carvalho L, Nadruz W, Quinaglia T, Kimura-Medorima S. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovascular Diabetology 2022, 21: 147. PMID: 35933413, PMCID: PMC9356512, DOI: 10.1186/s12933-022-01584-8.Peer-Reviewed Original ResearchConceptsFlow-mediated dilationEndothelial functionPost-treatment changesPlasma levelsPlasma levels of nitric oxide metabolitesBackgroundSodium-glucose cotransporter 2 inhibitorsCardiovascular eventsInhibitors reduce cardiovascular eventsLevels of nitric oxide metabolitesE groupPlasma levels of nitrateEE groupHigh-risk patientsProprotein convertase subtilisin/kexin 9Nitric oxide metabolitesRandomized active-controlled trialActive-controlled trialReduce cardiovascular eventsType 2 diabetesPCSK9-iSGLT2i treatmentPrimary endpointSGLT2-iEndothelial dysfunctionSecondary outcomes
2019
P4626Neuronal nitric oxide sintetase polymorphism increases sympathetic activity and recurrent cardiovascular events after myocardial infarction
Oliveira E, Munhoz D, Carvalho L, Moura F, Machado-Silva W, Figueiredo V, Nobrega O, Sposito A. P4626Neuronal nitric oxide sintetase polymorphism increases sympathetic activity and recurrent cardiovascular events after myocardial infarction. European Heart Journal 2019, 40: ehz745.1008. DOI: 10.1093/eurheartj/ehz745.1008.Peer-Reviewed Original ResearchST-elevation myocardial infarctionMajor cardiovascular eventsT allele carriersFlow-mediated dilationRecurrent major cardiovascular eventsCardiovascular eventsSympathetic activityClinical impactT alleleAcute phase of ST-elevation myocardial infarctionAssociated with increased sympathetic toneDecreased FMDMyocardial infarctionClinical follow-upCox regression analysisIncreased sympathetic activityNitric oxideRecurrent cardiovascular eventsAutonomic nervous system modulationCardiac sudden deathElevation myocardial infarctionDecreased parasympathetic activityPeripheral nervous systemSimvastatin doseSympathetic tone
2013
Validation of HOMA2S in acute phase of myocardial infarction, based on euglycemic-hyperinsulinemic clamp
Carvalho L, Moura F, Gomes N, Sposito A. Validation of HOMA2S in acute phase of myocardial infarction, based on euglycemic-hyperinsulinemic clamp. European Heart Journal 2013, 34: p1272. DOI: 10.1093/eurheartj/eht308.p1272.Peer-Reviewed Original ResearchAcute phase of MIEuglycemic-hyperinsulinemic clampPhase of MIMyocardial infarctionInsulin sensitivityAcute phaseST-segment elevation MIROC curveEvaluate blood glucose levelsArea under the curveAcute phase of myocardial infarctionHomeostasis model assessmentBland-Altman graphsPhase of myocardial infarctionBland-Altman analysisLinear regressionHyperinsulinemic-euglycemic clampHeart StudyGold standard methodBlood glucose levelsNondiabetic patientsStressful situationsCardiovascular eventsElevation MIEndothelial function
2012
Atherosclerotic disease in octogenarians: A challenge for science and clinical practice
Freitas W, Carvalho L, Moura F, Sposito A. Atherosclerotic disease in octogenarians: A challenge for science and clinical practice. Atherosclerosis 2012, 225: 281-289. PMID: 22858284, DOI: 10.1016/j.atherosclerosis.2012.06.070.Peer-Reviewed Original Research